Back to search

National and Kapodistrian University of Athens

Κλινική αξιολόγηση της έκφρασης του γονιδίου KLK6 που κωδικοποιεί την καλλικρεΐνη 6 στον καρκίνο του μαστού

Abstract

dc:description

Breast tumors exhibit vast heterogeneity reflected by diverse biological and molecular features, prognostic outcomes and response to therapy. Novel molecular markers that provide meaningful prognostic information for breast cancer patients are needed. According to previous research studies, expression of KLK family members is often associated with clinical outcome of breast cancer (BC) patients. More than that, Kallikrein-related peptidase 6 (KLK6) was previously reported to be implicated in BC and thus may prove a useful molecular tool for clinical management. The purpose of the present study was to assess the clinical value and prognostic potential of KLK6 mRNA expression in BC.Total RNA was extracted from 165 breast tumors, as well as 100 adjacent non-cancerous tumor specimens. After complementary DNA (cDNA) synthesis and following quality control, KLK6 mRNA levels were analysed using quantitative real-time PCR. Receiver operating characteristic curves were constructed in order to assess the ability of KLK6 mRNA expression levels to differentiate between molecular BC subtypes. Survival analyses, using DFS as endpoint, were performed at the univariate and multivariate levels. Publicly available BC databases and online survival analysis tools were used to validate our findings.A significant downregulation of KLK6 mRNA expression was observed in BC tissue sections compared to the non-cancerous component (P<0.001). The expression of KLK6 is positively associated with tumor grade (P=0.038) and the gene is overexpressed in aggressive phenotypes such as TNBC and HER2-positive tumors (P<0.001). Aberrant KLK6 expression predicts the clinical outcome of BC patients in terms of DFS, independently of currently used prognostic markers (HR=7.11, 95%CI = 1.19-42.45). The differential expression of KLK6 and its association with unfavourable outcome in BC patients was validated via in silico analyses.To our knowledge, this is the first study to provide evidence of the clinical value and prognostic potential of KLK6 mRNA expression in BC. Although an independent external cohort is necessary to confirm our findings, we indicate the potential of KLK6 to discriminate between BC subtypes and its robust and independent association with BC patient outcome.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2018

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Haritos, Christoforos
  • Χαρίτος, Χριστόφορος

Subjects

dc:subject × 14

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/43126

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Haritos, Christoforos; Χαρίτος, Χριστόφορος. Κλινική αξιολόγηση της έκφρασης του γονιδίου KLK6 που κωδικοποιεί την καλλικρεΐνη 6 στον καρκίνο του μαστού. National and Kapodistrian University of Athens, 2018. http://hdl.handle.net/10442/hedi/43126